bepridil has been researched along with Coronary Heart Disease in 26 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Excerpt | Relevance | Reference |
---|---|---|
"The pharmacokinetics of intravenous bepridil (1-[2-(N-benzylanilino)-1-(isobutoxymethyl)ethyl]pyrrolidine ) were studied in 16 patients undergoing cardiac catheterization for evaluation of coronary disease, all with normal base-line hemodynamic and renal functions." | 7.67 | Pharmacokinetics of intravenous bepridil in patients with coronary disease. ( Alpert, JS; Benotti, JR; Brady, PM; Lesko, LJ; McCue, JE; Ockene, IS; Weiner, BH, 1986) |
"Bepridil (Cordium) is a calcium channel blocker which has been demonstrated to be effective in the preventive treatment of angina." | 6.68 | [Comparison of anti-ischemic effect of bepridil and diltiazem evaluated by exercise test in patients with coronary disease. A multicenter study. Groupe d'Investigateurs]. ( Quilliet, L; Sellier, P, 1997) |
" The patients were divided into 3 groups according to the arrhythmias observed and the dosage used." | 6.66 | [Efficacy of oral bepridil in ventricular arrhythmias in stable coronary insufficiency]. ( Brechenmacher, C; Deroubaix, G; Dupont, T; Moulinie, E; Pasco, A; Pellet, J; Rio, A; Rossignol, B, 1985) |
"A contrast medium-induced coronary reactive hyperemia (HPR) evidenced an increased hyperemic volume from 9." | 5.27 | Alterations in contrast medium-induced coronary reactive hyperemia after bepridil in patients with coronary artery disease. ( Blanchet, F; Foult, JM; Huyghebaert, MF; Nitenberg, A; Zouiouèche, S, 1985) |
"The pharmacokinetics of intravenous bepridil (1-[2-(N-benzylanilino)-1-(isobutoxymethyl)ethyl]pyrrolidine ) were studied in 16 patients undergoing cardiac catheterization for evaluation of coronary disease, all with normal base-line hemodynamic and renal functions." | 3.67 | Pharmacokinetics of intravenous bepridil in patients with coronary disease. ( Alpert, JS; Benotti, JR; Brady, PM; Lesko, LJ; McCue, JE; Ockene, IS; Weiner, BH, 1986) |
"Bepridil (Cordium) is a calcium channel blocker which has been demonstrated to be effective in the preventive treatment of angina." | 2.68 | [Comparison of anti-ischemic effect of bepridil and diltiazem evaluated by exercise test in patients with coronary disease. A multicenter study. Groupe d'Investigateurs]. ( Quilliet, L; Sellier, P, 1997) |
" The patients were divided into 3 groups according to the arrhythmias observed and the dosage used." | 2.66 | [Efficacy of oral bepridil in ventricular arrhythmias in stable coronary insufficiency]. ( Brechenmacher, C; Deroubaix, G; Dupont, T; Moulinie, E; Pasco, A; Pellet, J; Rio, A; Rossignol, B, 1985) |
"Bepridil is a calcium antagonist with a unique chemical structure and properties that differ from other calcium antagonists (e." | 2.38 | Hemodynamic effects of bepridil in patients with coronary artery disease. ( Narahara, KA, 1992) |
"Bepridil was more effective than verapamil in protecting against this ischaemic damage." | 1.27 | Protective effects of the calmodulin antagonist bepridil on ischaemia induced in the rat myocardium. ( Hidaka, H; Itoh, H; Kusagawa, M; Shikano, K, 1986) |
"Treatment with bepridil before and during ischemia did not improve recovery of cardiac function, tissue energy reserves, or mitochondrial function upon reperfusion with control buffer." | 1.27 | Comparison of the effects of bepridil and diltiazem upon globally ischemic rat hearts. ( Harwell, T; Maiorano, P; Watts, J, 1987) |
"A contrast medium-induced coronary reactive hyperemia (HPR) evidenced an increased hyperemic volume from 9." | 1.27 | Alterations in contrast medium-induced coronary reactive hyperemia after bepridil in patients with coronary artery disease. ( Blanchet, F; Foult, JM; Huyghebaert, MF; Nitenberg, A; Zouiouèche, S, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 19 (73.08) | 18.7374 |
1990's | 7 (26.92) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kasanuki, H | 1 |
Hill, JA | 2 |
O'Brien, JT | 1 |
Scott, E | 1 |
Conti, CR | 1 |
Pepine, CJ | 2 |
Sellier, P | 1 |
Quilliet, L | 1 |
Narahara, KA | 1 |
van Amsterdam, FT | 2 |
Punt, NC | 2 |
Haas, M | 2 |
Zaagsma, J | 2 |
Hashimoto, H | 1 |
Satoh, N | 1 |
Nakashima, M | 1 |
Puech, P | 1 |
Coumel, P | 1 |
Maison Blanche, P | 1 |
Coudray, P | 1 |
Massingham, R | 1 |
Van Zwieten, PA | 2 |
Remme, WJ | 2 |
Kruyssen, DA | 1 |
Van Hoogenhuyze, DC | 2 |
Hofman, B | 1 |
Krauss, XH | 2 |
Storm, CJ | 2 |
Shikano, K | 1 |
Kusagawa, M | 1 |
Itoh, H | 1 |
Hidaka, H | 1 |
Reifart, N | 1 |
Marston, W | 1 |
Zierler, MK | 1 |
Taylor, AD | 1 |
Kaltenbach, M | 1 |
Khuri, SF | 1 |
Boddeke, EW | 1 |
Wilffert, B | 1 |
Heynis, JB | 1 |
Hugtenburg, JG | 1 |
Jap, WT | 1 |
Veldsema-Currie, RD | 1 |
Beaughard, M | 1 |
Lamar, JC | 1 |
Piris, P | 1 |
Tisne-Versailles, J | 1 |
Watts, JA | 1 |
Lesko, LJ | 1 |
Benotti, JR | 1 |
Alpert, JS | 1 |
Brady, PM | 1 |
McCue, JE | 1 |
Weiner, BH | 1 |
Ockene, IS | 1 |
Watts, J | 1 |
Maiorano, P | 1 |
Harwell, T | 1 |
Hofman, A | 1 |
Kruyssen, HA | 1 |
Josephson, MA | 1 |
Mody, T | 1 |
Coyle, K | 1 |
Singh, BN | 1 |
Haerer, VW | 1 |
Stauch, M | 1 |
Foult, JM | 1 |
Nitenberg, A | 1 |
Blanchet, F | 1 |
Zouiouèche, S | 1 |
Huyghebaert, MF | 1 |
Tamari, I | 1 |
Borer, JS | 1 |
Moses, JW | 1 |
Goldberg, HL | 1 |
Fisher, J | 1 |
Wallis, JB | 1 |
Halle, A | 1 |
Jackson, CV | 1 |
Mitsos, SE | 1 |
Simpson, PJ | 1 |
Driscoll, EM | 1 |
Lucchesi, BR | 2 |
Lynch, JJ | 1 |
Rahwan, RG | 1 |
Rio, A | 1 |
Pasco, A | 1 |
Dupont, T | 1 |
Deroubaix, G | 1 |
Moulinie, E | 1 |
Rossignol, B | 1 |
Pellet, J | 1 |
Brechenmacher, C | 1 |
3 reviews available for bepridil and Coronary Heart Disease
Article | Year |
---|---|
[New generation of antiarrhythmic drug].
Topics: Amiodarone; Anti-Arrhythmia Agents; Bepridil; Coronary Disease; Humans; Randomized Controlled Trials | 1994 |
Hemodynamic effects of bepridil in patients with coronary artery disease.
Topics: Bepridil; Coronary Disease; Hemodynamics; Humans; Oxygen Consumption | 1992 |
Bepridil: a pharmacological reappraisal of its potential beneficial effects in angina and tissue protection following ischemia.
Topics: Angina Pectoris; Animals; Bepridil; Coronary Disease; Humans | 1989 |
5 trials available for bepridil and Coronary Heart Disease
Article | Year |
---|---|
Effects of bepridil on exercise tolerance in chronic stable angina: a double-blind, randomized, placebo-controlled, crossover trial.
Topics: Aged; Angina Pectoris; Bepridil; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Clinical | 1984 |
Effects of bepridil on the resting electrocardiogram.
Topics: Aged; Angina Pectoris; Anti-Arrhythmia Agents; Bepridil; Clinical Trials as Topic; Coronary Disease; | 1984 |
[Comparison of anti-ischemic effect of bepridil and diltiazem evaluated by exercise test in patients with coronary disease. A multicenter study. Groupe d'Investigateurs].
Topics: Bepridil; Calcium Channel Blockers; Coronary Disease; Diltiazem; Double-Blind Method; Exercise Test; | 1997 |
[Comparative study of the mid-term electrocardiographic and clinical tolerability of bepridil versus diltiazem in patients with coronary disease].
Topics: Aged; Bepridil; Coronary Disease; Diltiazem; Double-Blind Method; Electrocardiography; Electrocardio | 1990 |
[Efficacy of oral bepridil in ventricular arrhythmias in stable coronary insufficiency].
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bepridil; Clinical Trials | 1985 |
18 other studies available for bepridil and Coronary Heart Disease
Article | Year |
---|---|
Stereoisomers of calcium antagonists distinguish a myocardial and vascular mode of protection against cardiac ischemic injury.
Topics: Animals; Bepridil; Calcium Channel Blockers; Cardiomyopathies; Coronary Circulation; Coronary Diseas | 1990 |
Effects of bepridil and lidocaine on the intraventricular conduction in acutely ischaemic and infarcted canine myocardium.
Topics: Animals; Bepridil; Coronary Disease; Coronary Vessels; Dogs; Electrophysiology; Heart; Heart Conduct | 1990 |
Calcium antagonists show two modes of protection in ischemic heart failure.
Topics: Animals; Bepridil; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diastole; Dose- | 1990 |
Acute hemodynamic and antiischemic properties of intravenous bepridil in coronary artery disease.
Topics: Adult; Aged; Bepridil; Calcium Channel Blockers; Cardiac Catheterization; Cardiac Pacing, Artificial | 1989 |
Protective effects of the calmodulin antagonist bepridil on ischaemia induced in the rat myocardium.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Bepridil; Calmodulin; Coronary Disease; Drug In | 1986 |
Effects of bepridil on regional myocardial ischemia and comparison with verapamil.
Topics: Animals; Bepridil; Calcium Channel Blockers; Carbon Dioxide; Coronary Circulation; Coronary Disease; | 1986 |
The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts.
Topics: Adenosine Triphosphate; Animals; Bepridil; Calcium Channel Blockers; Coronary Circulation; Coronary | 1988 |
Effects of bepridil and nifedipine on regional myocardial contractility during ischaemia in anaesthetized dogs.
Topics: Anesthesia; Animals; Bepridil; Coronary Circulation; Coronary Disease; Dogs; Myocardial Contraction; | 1986 |
Protection of ischemic hearts by Ca2+ antagonists.
Topics: Animals; Bepridil; Calcium; Calcium Channel Blockers; Coronary Disease; Diltiazem; Energy Metabolism | 1986 |
Pharmacokinetics of intravenous bepridil in patients with coronary disease.
Topics: Aged; Bepridil; Calcium Channel Blockers; Coronary Disease; Female; Humans; Injections, Intravenous; | 1986 |
Comparison of the effects of bepridil and diltiazem upon globally ischemic rat hearts.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Bepridil; Calcium; Coronary Disease; Diltiaz | 1987 |
Dose related coronary and systemic haemodynamic effects of intravenous bepridil in patients with coronary artery disease.
Topics: Adult; Angina Pectoris; Anti-Arrhythmia Agents; Bepridil; Coronary Circulation; Coronary Disease; Do | 1987 |
Effects on hemodynamics and left ventricular ejection fraction of intravenous bepridil for impaired left ventricular function secondary to coronary artery disease.
Topics: Adult; Aged; Bepridil; Calcium Channel Blockers; Coronary Disease; Depression, Chemical; Dose-Respon | 1987 |
[Hemodynamic effects of a new calcium antagonist, bepridil, in patients with coronary artery disease].
Topics: Bepridil; Calcium Channel Blockers; Coronary Disease; Hemodynamics; Humans; Middle Aged; Pulmonary W | 1987 |
Alterations in contrast medium-induced coronary reactive hyperemia after bepridil in patients with coronary artery disease.
Topics: Adult; Bepridil; Coronary Circulation; Coronary Disease; Female; Humans; Hyperemia; Ioxaglic Acid; M | 1985 |
Hemodynamic assessment of intravenous bepridil administration in ischemic heart disease.
Topics: Adult; Aged; Bepridil; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Female; Hemodynam | 1985 |
Effects of bepridil on regional and global myocardial ischemia/reperfusion-induced injury.
Topics: Adenosine Triphosphate; Animals; Bepridil; Cats; Coronary Circulation; Coronary Disease; Dogs; Femal | 1985 |
Antifibrillatory actions of bepridil and butyl-MDI, two intracellular calcium antagonists.
Topics: Animals; Anti-Arrhythmia Agents; Bepridil; Calcium; Calcium Channel Blockers; Coronary Circulation; | 1985 |